Related Experiment Video
Updated: Aug 15, 2025

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
Antagonistic effect of cyclin-dependent kinases and a calcium-dependent phosphatase on polyglutamine-expanded
Diana Piol1,2,3,4, Laura Tosatto4,5, Emanuela Zuccaro1,2,3
1Department of Biomedical Sciences, University of Padova, Padova, Italy.
Abstract:
Spinal and bulbar muscular atrophy is caused by polyglutamine (polyQ) expansions in androgen receptor (AR), generating gain-of-function toxicity that may involve phosphorylation. Using cellular and animal models, we investigated what kinases and phosphatases target polyQ-expanded AR, whether polyQ expansions modify AR phosphorylation, and how this contributes to neurodegeneration. Mass spectrometry showed that polyQ expansions preserve native phosphorylation and increase phosphorylation at conserved sites controlling AR stability and transactivation. In small-molecule screening, we identified that CDC25/CDK2 signaling could enhance AR phosphorylation, and the calcium-sensitive phosphatase calcineurin had opposite effects. Pharmacologic and genetic manipulation of these kinases and phosphatases modified polyQ-expanded AR function and toxicity in cells, flies, and mice. Ablation of CDK2 reduced AR phosphorylation in the brainstem and restored expression of Myc and other genes involved in DNA damage, senescence, and apoptosis, indicating that the cell cycle-regulated kinase plays more than a bystander role in SBMA-vulnerable postmitotic cells.
Insights
Spinal and bulbar muscular atrophy involves androgen receptor (AR) phosphorylation. Targeting cell cycle kinases like CDK2 reduces AR phosphorylation, mitigating neurodegeneration in cellular and animal models.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Spinal and bulbar muscular atrophy (SBMA) stems from polyglutamine (polyQ) expansions in the androgen receptor (AR).
- This leads to toxic gain-of-function, potentially mediated by AR phosphorylation.
- Understanding AR phosphorylation in SBMA is crucial for therapeutic development.
Purpose of the Study:
- Investigate kinases and phosphatases targeting polyQ-expanded AR.
- Determine if polyQ expansions alter AR phosphorylation.
- Elucidate the role of AR phosphorylation in SBMA neurodegeneration.
Main Methods:
- Utilized cellular and animal models (flies, mice) of SBMA.
- Employed mass spectrometry to analyze AR phosphorylation.
- Conducted small-molecule screening to identify relevant signaling pathways.
- Performed pharmacologic and genetic manipulation of kinases and phosphatases.
Main Results:
- PolyQ expansions preserve native AR phosphorylation and increase it at key sites.
- CDC25/CDK2 signaling enhances AR phosphorylation; calcineurin reduces it.
- Modulating these pathways affected polyQ-AR function and toxicity in SBMA models.
- CDK2 ablation decreased brainstem AR phosphorylation and restored gene expression linked to DNA damage and apoptosis.
Conclusions:
- Cell cycle-regulated kinase CDK2 plays a significant role in SBMA pathogenesis.
- Targeting CDK2 may offer a therapeutic strategy for SBMA by reducing AR phosphorylation.
- Findings highlight the importance of AR phosphorylation in neurodegeneration associated with SBMA.
Related Concept Videos
GPCRs Regulate Adenylyl Cylase Activity
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
GPCR Desensitization
Anaphase Promoting Complex
Amplifying Signals via Enzymatic Cascade
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...

